Terns Pharmaceuticals, Inc.
We are a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. NASH is a severe form of non-alcoholic fatty liver disease, or NAFLD, that affects up to 15 million people in the United States, and up to 6% of the global population, for which there is currently no approved therapy in the United States or Europe.
Our most advanced program is TERN-101, a liver-distributed, non-bile acid Farnesoid X Receptor agonist that has demonstrated sustained liver FXR activation, as well as a favorable tolerability profile across multiple Phase 1 clinical trials. We intend to start our Phase 1b clinical trial of TERN-201 in NASH patients in the first half of 2021 and expect top-line data in the first half of 2022.
(Note: Terns Pharmaceuticals upsized its IPO at pricing on Feb. 4, 2021, to 7.5 million shares, up from 6.25 million shares, at $17 – the high end of its $15-to-$17 price range.)
|Address||1065 East Hillsdale Blvd., Suite 100 Foster City, California 94404|
|Phone Number||(650) 525-5535|
|View Prospectus:||Terns Pharmaceuticals, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-39.9 mil (last 12 months)|
|Price range||$17.00 - $17.00|
|Est. $ Volume||$127.5 mil|
|Manager / Joint Managers||J.P. Morgan/ Goldman Sachs/ Cowen and Company|
|Expected To Trade:||2/5/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|